Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography.
A considerable number of human and animal studies have implied the importance of dopamine system and alterations in dopamine receptors in the context of alcoholism. However, it has remained unclear if the alcohol-abuse related dopaminergic deficit is specifically associated with certain receptor subtype. The aim of this study was to compare putative alterations of dopamine D(1) receptors in caudate and putamen of nine type 1 alcoholics, eight type 2 alcoholics and 10 healthy controls by using [(3)H]SCH 23390 as a radioligand in postmortem human whole hemisphere autoradiography. In addition, we compared the present results to our earlier studies on dopamine transporters and dopamine D(2) receptors in these same subjects and evaluated the putative correlations of dopamine D(1) receptor densities between the nucleus accumbens and the above-mentioned structures. Our results show that alcoholics do not have significantly different striatal dopamine D(1) receptor densities compared to controls. Neither were there any significant correlations between the dopamine D(1) receptors and the two other dopamine binding sites. However, the correlations of the dopamine D(1) receptors between nucleus accumbens and dorsal striatal structures were consistently and mostly statistically significantly positive in alcoholics, but not in controls, which may suggest some pathology related to addiction. In addition, considering the facts that dopamine D(1) receptors were more abundant in the mesolimbic nucleus accumbens than in the caudate or putamen and that there was a strong tendency towards lower binding among type 1 alcoholics may suggest the importance of dopamine D(1) receptors in reward and/or alcoholism.
Tupala
Erkki
E
Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, FI-70240 Kuopio, Finland. erkki.tupala@niuva.fi
Tiihonen
Jari
J
D000328:Adult; D000437:Alcoholism / Q000378:metabolism*; D001345:Autoradiography; D001549:Benzamides / Q000378:metabolism / Q000494:pharmacology; D001552:Benzazepines / Q000378:metabolism / Q000494:pharmacology; D003287:Contrast Media / Q000378:metabolism / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000378:metabolism*; D009662:Nortropanes / Q000378:metabolism / Q000494:pharmacology; D009714:Nucleus Accumbens / Q000378:metabolism*; D011759:Pyrrolidines / Q000378:metabolism / Q000494:pharmacology; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D012201:Reward; D014316:Tritium
D001549:Benzamides; D001552:Benzazepines; D003287:Contrast Media; D018492:Dopamine Antagonists; D007457:Iodine Radioisotopes; C113010:N-(3-iodoprop-2-enyl)-2-beta-carbomethoxy-3-(4-methylphenyl)nortropane; D009662:Nortropanes; D011759:Pyrrolidines; D017447:Receptors, Dopamine D1; D014316:Tritium; C063525:epidepride